Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer

M. S. Soloway

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Cure following surgery of bladder cancer is limited by recurrence of the original tumor or by the development of new primary tumors. Transitional cell carcinoma of the bladder induced in C3H/HeJ mice by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(FANFT) closely resemble their human counterpart and have been used to evaluate the effect of chemotherapy and/or BCG on the induction and growth of these tumors. Three hunderd five mice were divided into a control group of 30 and 11 treatment groups of 25. Therapy was initiated at 5 and 7 months after FANFT. The first tumors in this system are observed at 8 months with an expected incidence of 70-90% by 11 months. Therapy consisted of: BCG; cyclophosphamide; cyclophosphamide + BCG; cyclophosphamide + 5-FU; cyclophosphamide + adriamycin; and adriamycin. All mice were killed after 11 months on FANFT. Bladders were weighed and the tumors were staged. Tumor incidence was reduced by only two regimens: adriamycin and cyclophosphamide + adriamycin. Cyclophosphamide significantly reduced subsequent tumor volume compared with the control group, with the effect being more pronounced in mice beginning treatment at 5 months. The combination regimens were superior to cyclophosphamide alone. BCG did not potentiate the antitumor action of cyclophosphamide and, when used alone, actually enhanced tumor growth (P<0.025). The use of BCG immunotherapy should be cautioned, but the effectiveness of the antineoplastic drugs suggests their use in clinical trials in patients with bladder cancer.

Original languageEnglish
Title of host publicationNational Cancer Institute Monograph
Pages327-332
Number of pages6
VolumeMonogr. 49
StatePublished - Dec 1 1978
Externally publishedYes

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Cyclophosphamide
FANFT
Drug Therapy
Doxorubicin
Neoplasms
Urinary Bladder
Control Groups
Inbred C3H Mouse
Transitional Cell Carcinoma
Incidence
Therapeutics
Growth
Tumor Burden
Fluorouracil
Antineoplastic Agents
Immunotherapy
Clinical Trials
Recurrence

ASJC Scopus subject areas

  • Cancer Research

Cite this

Soloway, M. S. (1978). Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer. In National Cancer Institute Monograph (Vol. Monogr. 49, pp. 327-332)

Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer. / Soloway, M. S.

National Cancer Institute Monograph. Vol. Monogr. 49 1978. p. 327-332.

Research output: Chapter in Book/Report/Conference proceedingChapter

Soloway, MS 1978, Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer. in National Cancer Institute Monograph. vol. Monogr. 49, pp. 327-332.
Soloway MS. Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer. In National Cancer Institute Monograph. Vol. Monogr. 49. 1978. p. 327-332
Soloway, M. S. / Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer. National Cancer Institute Monograph. Vol. Monogr. 49 1978. pp. 327-332
@inbook{adcccf93283b4c19bd2313e7fd5a0526,
title = "Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer",
abstract = "Cure following surgery of bladder cancer is limited by recurrence of the original tumor or by the development of new primary tumors. Transitional cell carcinoma of the bladder induced in C3H/HeJ mice by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(FANFT) closely resemble their human counterpart and have been used to evaluate the effect of chemotherapy and/or BCG on the induction and growth of these tumors. Three hunderd five mice were divided into a control group of 30 and 11 treatment groups of 25. Therapy was initiated at 5 and 7 months after FANFT. The first tumors in this system are observed at 8 months with an expected incidence of 70-90{\%} by 11 months. Therapy consisted of: BCG; cyclophosphamide; cyclophosphamide + BCG; cyclophosphamide + 5-FU; cyclophosphamide + adriamycin; and adriamycin. All mice were killed after 11 months on FANFT. Bladders were weighed and the tumors were staged. Tumor incidence was reduced by only two regimens: adriamycin and cyclophosphamide + adriamycin. Cyclophosphamide significantly reduced subsequent tumor volume compared with the control group, with the effect being more pronounced in mice beginning treatment at 5 months. The combination regimens were superior to cyclophosphamide alone. BCG did not potentiate the antitumor action of cyclophosphamide and, when used alone, actually enhanced tumor growth (P<0.025). The use of BCG immunotherapy should be cautioned, but the effectiveness of the antineoplastic drugs suggests their use in clinical trials in patients with bladder cancer.",
author = "Soloway, {M. S.}",
year = "1978",
month = "12",
day = "1",
language = "English",
volume = "Monogr. 49",
pages = "327--332",
booktitle = "National Cancer Institute Monograph",

}

TY - CHAP

T1 - Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer

AU - Soloway, M. S.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - Cure following surgery of bladder cancer is limited by recurrence of the original tumor or by the development of new primary tumors. Transitional cell carcinoma of the bladder induced in C3H/HeJ mice by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(FANFT) closely resemble their human counterpart and have been used to evaluate the effect of chemotherapy and/or BCG on the induction and growth of these tumors. Three hunderd five mice were divided into a control group of 30 and 11 treatment groups of 25. Therapy was initiated at 5 and 7 months after FANFT. The first tumors in this system are observed at 8 months with an expected incidence of 70-90% by 11 months. Therapy consisted of: BCG; cyclophosphamide; cyclophosphamide + BCG; cyclophosphamide + 5-FU; cyclophosphamide + adriamycin; and adriamycin. All mice were killed after 11 months on FANFT. Bladders were weighed and the tumors were staged. Tumor incidence was reduced by only two regimens: adriamycin and cyclophosphamide + adriamycin. Cyclophosphamide significantly reduced subsequent tumor volume compared with the control group, with the effect being more pronounced in mice beginning treatment at 5 months. The combination regimens were superior to cyclophosphamide alone. BCG did not potentiate the antitumor action of cyclophosphamide and, when used alone, actually enhanced tumor growth (P<0.025). The use of BCG immunotherapy should be cautioned, but the effectiveness of the antineoplastic drugs suggests their use in clinical trials in patients with bladder cancer.

AB - Cure following surgery of bladder cancer is limited by recurrence of the original tumor or by the development of new primary tumors. Transitional cell carcinoma of the bladder induced in C3H/HeJ mice by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(FANFT) closely resemble their human counterpart and have been used to evaluate the effect of chemotherapy and/or BCG on the induction and growth of these tumors. Three hunderd five mice were divided into a control group of 30 and 11 treatment groups of 25. Therapy was initiated at 5 and 7 months after FANFT. The first tumors in this system are observed at 8 months with an expected incidence of 70-90% by 11 months. Therapy consisted of: BCG; cyclophosphamide; cyclophosphamide + BCG; cyclophosphamide + 5-FU; cyclophosphamide + adriamycin; and adriamycin. All mice were killed after 11 months on FANFT. Bladders were weighed and the tumors were staged. Tumor incidence was reduced by only two regimens: adriamycin and cyclophosphamide + adriamycin. Cyclophosphamide significantly reduced subsequent tumor volume compared with the control group, with the effect being more pronounced in mice beginning treatment at 5 months. The combination regimens were superior to cyclophosphamide alone. BCG did not potentiate the antitumor action of cyclophosphamide and, when used alone, actually enhanced tumor growth (P<0.025). The use of BCG immunotherapy should be cautioned, but the effectiveness of the antineoplastic drugs suggests their use in clinical trials in patients with bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0018216279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018216279&partnerID=8YFLogxK

M3 - Chapter

VL - Monogr. 49

SP - 327

EP - 332

BT - National Cancer Institute Monograph

ER -